Cisplatin (Cervical Cancer) - Analysis and Forecasts to 2020

Date: October 1, 2011
Pages: 33
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C02813D6A5FEN
Leaflet:

Download PDF Leaflet

Cisplatin (Cervical Cancer) - Analysis and Forecasts to 2020
Cisplatin (Cervical Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Cisplatin (Cervical Cancer) - Analysis and Forecasts to 2020” provides Cisplatin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Summary
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Cisplatin including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Cisplatin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Cisplatin in the seven major markets

Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Cervical Cancer Market
2.2 Epidemiology
2.3 Etiology
  2.3.1 HPV Infections
  2.3.2 Lack of Regular Papanicolaou (pap) Tests
  2.3.3 Smoking
  2.3.4 Sexual History
  2.3.5 Birth Control Pills
2.4 GlobalData Report Guidance

3 CERVICAL CANCER: MARKET CHARACTERIZATION

3.1 Cervical Cancer Market
3.2 Cervical Cancer Market Forecasts and CAGR
3.3 Drivers and Barriers for the Cervical Cancer Market
  3.3.1 Life Threatening Disease
  3.3.2 Low Incidence
  3.3.3 High Use of off-labeled drugs
  3.3.4 Early Screening
  3.3.5 Emergence of Vaccines

4 TUMOR-NODE-METASTASES(TNM) CLASSIFICATION OF CERVICAL CANCER

5 CISPLATIN

5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Approval History of Cisplatin
5.5 Factors Affecting Sales of Cisplatin
  5.5.1 Low Competition
  5.5.2 Dominance of Platinum Drugs
  5.5.3 Combination Therapy
  5.5.4 Stable Growth in Future
  5.5.5 Drug Risk Benefit Score
  5.5.6 Efficacy
  5.5.7 Safety
  5.5.8 Compliance
  5.5.9 Dosing Convenience
5.6 Intensity of Competition
5.7 Sales Forecasts
  5.7.1 Target Patient Pool of Cisplatin
  5.7.2 Dosing
  5.7.3 Market Penetration
  5.7.4 Annual Cost of Therapy
  5.7.5 Sales Projections of Cisplatin

6 CERVICAL CANCER MARKET: APPENDIX

6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
  6.3.1 Coverage
  6.3.2 Secondary Research
  6.3.3 Forecasting
  6.3.4 Number of Patients Approved to take the Drug
  6.3.5 Net Penetration of Drug
  6.3.6 Net Annual Dosing
  6.3.7 Annual Cost of Therapy
  6.3.8 Primary Research
  6.3.9 Expert Panels
6.4 Contact Us
6.5 Disclaimer
6.6 Sources

LIST OF TABLES

Table 1: Cervical Cancer, Estimated Incidences and Mortality, 2010–2020
Table 2: Cervical Cancer, the US, EU-5 and Japan, Market Size Forecast ($bn), 2009–2020
Table 3: Results of GOG-0110 Trial
Table 4: Results of GOG-0169 Trial
Table 5: Results of GOG-0179 Trial
Table 6: Details of GOG-0204 Trial
Table 7: Results of GOG-0204 Trial
Table 8: Drug Risk Benefit Score of Cisplatin
Table 9: Annual Cost of Therapy
Table 10: Cisplatin, Cervical Cancer, Global, Sales Estimates ($m), 2002–2020
Table 11: Cisplatin, Cervical Cancer, the US, Sales Estimates ($m), 2002–2020
Table 12: Cisplatin, Cervical Cancer, the US, Sales Estimates ($m), 2002–2020
Table 13: Cisplatin, Cervical Cancer, France, Sales Estimates ($m), 2002–2020
Table 14: Cisplatin, Cervical Cancer, Germany, Sales Estimates ($m), 2002–2020
Table 15: Cisplatin, Cervical Cancer, Italy, Sales Estimates ($m), 2002–2020
Table 16: Cisplatin, Cervical Cancer, Spain, Sales Estimates ($m), 2002–2020
Table 17: Cisplatin, Cervical Cancer, Japan, Sales Estimates ($m), 2002–2020

LIST OF FIGURES

Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2008
Figure 2: Difference Between Percentage Distribution of Incidence and Mortality of Most Commonly Diagnosed Cancers, Worldwide, 2008
Figure 3: Cervical Cancer, the US, EU-5 and Japan, Market Size Forecast ($bn), 2009–2020
Figure 4: Classification of Cervical Cancer
Figure 5: TNM Staging Classification
Figure 6: Classification of Cervical Cancer
Figure 7: Drug Model Diagram of Cisplatin
Figure 8: Cisplatin, Cervical Cancer, Global, Sales Estimates ($m), 2002–2020
Figure 9: Cisplatin, Cervical Cancer, the US, Sales Estimates ($m), 2002–2020
Figure 10: Cisplatin, Cervical Cancer, the UK, Sales Estimates ($m), 2002–2020
Figure 11: Cisplatin, Cervical Cancer, France, Sales Estimates ($m), 2002–2020
Figure 12: Cisplatin, Cervical Cancer, Germany, Sales Estimates ($m), 2002–2020
Figure 13: Cisplatin, Cervical Cancer, Italy, Sales Estimates ($m), 2002–2020
Figure 14: Cisplatin, Cervical Cancer, Spain, Sales Estimates ($m), 2002–2020
Figure 15: Cisplatin, Cervical Cancer, Japan, Sales Estimates ($m), 2002–2020
Figure 16: Cisplatin, Cervical Cancer, Global, Sales Distribution, 2020
Figure 17: Drug Model Diagram
Figure 18: Patients Approved for the Drug

Ask Your Question

Cisplatin (Cervical Cancer) - Analysis and Forecasts to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: